Pancreatic Cancer Research

ResearcherSeoul National UniversityActive in the last 2 years

Eui Kyu Chie

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-2027-7472; OpenAlex author ID A5013664294. Sources: OpenAlex.

Their work

Papers
20 (first author 3, last author 4)
Trials
0
Grants
0
Labs led
1
Collaborators
57
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: none · 2015: 2 papers · 2016: 2 papers · 2017: 3 papers · 2018: 1 paper · 2019: none · 2020: 1 paper · 2021: 3 papers · 2022: 2 papers · 2023: 1 paper · 2024: 2 papers · 2025: 1 paper · 2026: 1 paper

Papers 20

  1. Treatment Outcomes in Frail Patients with Advanced Pancreatic Ductal Adenocarcinoma: A Real-World Comparison of Gemcitabine, S-1, and Stereotactic Ablative Rad… Co-author DOI 10.1159/000552276↗
  2. Efficacy of Neoadjuvant Radiotherapy After Chemotherapy and the Optimal Interval from Radiotherapy to Surgery for Borderline Resectable and Resectable Pancreat… Co-author DOI 10.1245/s10434-024-16743-2↗
  3. Optimal timing of surgery after neoadjuvant treatment in borderline resectable pancreatic cancer. Co-author DOI 10.1002/jhbp.12049↗
  4. Safety and Efficacy of Neoadjuvant SABR in Pancreatic Cancer: Effect of Magnetic Resonance Imaging-Guided Respiratory-Gated Adaptive Radiation Therapy. Co-author DOI 10.1016/j.adro.2023.101312↗
  5. Impact of conversion surgery on survival in locally advanced pancreatic cancer patients treated with FOLFIRINOX chemotherapy. Co-author DOI 10.1002/jhbp.1050↗
  6. Consolidatory ablative stereotactic body radiation therapy after induction chemotherapy for unresectable pancreatic cancer: A single center experience. Last author DOI 10.3389/fonc.2022.974454↗
  7. Dosimetric evaluation of magnetic resonance imaging-guided adaptive radiation therapy in pancreatic cancer by extent of re-contouring of organs-at-risk. First author DOI 10.3857/roj.2022.00332↗
  8. Impact of sarcopenia on survival of pancreatic cancer patients treated with concurrent chemoradiotherapy. Last author DOI 10.1177/0300891620937795↗
  9. Phase II Trial of Postoperative Adjuvant Gemcitabine and Cisplatin Chemotherapy Followed by Chemoradiotherapy with Gemcitabine in Patients with Resected Pancre… First author DOI 10.4143/crt.2020.928↗
  10. Comparison of Clinical Outcomes of Borderline Resectable Pancreatic Cancer According to the Neoadjuvant Chemo-Regimens: Gemcitabine versus FOLFIRINOX. Co-author DOI 10.5009/gnl20070↗
  11. Survival benefit of adjuvant chemoradiotherapy for positive or close resection margin after curative resection of pancreatic adenocarcinoma. Last author DOI 10.1016/j.ejso.2020.07.029↗
  12. Oncological Benefits of Neoadjuvant Chemoradiation With Gemcitabine Versus Upfront Surgery in Patients With Borderline Resectable Pancreatic Cancer: A Prospect… Co-author DOI 10.1097/sla.0000000000002705↗
  13. Change in carbohydrate antigen 19-9 level as a prognostic marker of overall survival in locally advanced pancreatic cancer treated with concurrent chemoradioth… Co-author DOI 10.1007/s10147-017-1129-7↗
  14. Impact of Resection Margin Distance on Survival of Pancreatic Cancer: A Systematic Review and Meta-Analysis. Last author DOI 10.4143/crt.2016.336↗
  15. Chemoradiotherapy after gemcitabine plus erlotinib in patients with locally advanced pancreatic cancer. Co-author PMID 28952226↗
  16. Outcome Analysis of Chemoradiation in Unresectable Pancreatic Cancer Focusing on Treatment Sequencing Strategy. First author DOI 10.21873/anticanres.11125↗
  17. Concurrent Chemoradiotherapy Versus Chemotherapy Alone for Unresectable Locally Advanced Pancreatic Cancer: A Retrospective Cohort Study. Co-author DOI 10.4143/crt.2015.226↗
  18. Role of Adjuvant Radiotherapy in Left-Sided Pancreatic Cancer-Population-Based Analysis with Propensity Score Matching. Co-author DOI 10.1007/s11605-015-2941-x↗
  19. Prognostic value of splenic artery invasion in patients undergoing adjuvant chemoradiotherapy after distal pancreatectomy for pancreatic adenocarcinoma. Co-author DOI 10.4143/crt.2014.025↗
  20. Phase II clinical trial of induction chemotherapy with fixed dose rate gemcitabine and cisplatin followed by concurrent chemoradiotherapy with capecitabine for… Co-author DOI 10.1007/s00280-012-1918-7↗

Closest collaborators

The 25 strongest of 57 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jin‐Young Jang · 10 shared papers, 2015–2025 · strength 1.33
  2. Wooil Kwon · 7 shared papers, 2018–2025 · strength 1.11
  3. Do‐Youn Oh · 11 shared papers, 2015–2024 · strength 1.11
  4. Ji Kon Ryu · 5 shared papers, 2021–2026 · strength 0.99
  5. Woo Hyun Paik · 4 shared papers, 2021–2026 · strength 0.81
  6. Sang Hyub Lee · 4 shared papers, 2021–2024 · strength 0.70
  7. Hyun‐Cheol Kang · 3 shared papers, 2022–2024 · strength 0.64
  8. Kyubo Kim · 8 shared papers, 2015–2020 · strength 0.60
  9. Hongbeom Kim · 4 shared papers, 2020–2024 · strength 0.60
  10. In Rae Cho · 2 shared papers, 2024–2026 · strength 0.49
  11. Hye‐Sol Jung · 2 shared papers, 2024–2025 · strength 0.45
  12. Won‐Gun Yun · 2 shared papers, 2024–2025 · strength 0.45
  13. Yung‐Jue Bang · 6 shared papers, 2012–2021 · strength 0.38
  14. Yong‐Tae Kim · 2 shared papers, 2023–2024 · strength 0.38
  15. Jun Yeong Song · 2 shared papers, 2022–2024 · strength 0.38
  16. Sung Whan Ha · 6 shared papers, 2012–2021 · strength 0.37
  17. Kyung-Hun Lee · 4 shared papers, 2016–2021 · strength 0.34
  18. Joon Seong Park · 2 shared papers, 2018–2025 · strength 0.31
  19. Seock‐Ah Im · 5 shared papers, 2012–2021 · strength 0.31
  20. Chang Hyun Kim · 1 shared paper, 2026 · strength 0.29
  21. Jin Ho Choi MD · 1 shared paper, 2026 · strength 0.29
  22. Tae Seung Lee · 1 shared paper, 2026 · strength 0.29
  23. Jae Seung Kang · 2 shared papers, 2021–2023 · strength 0.29
  24. Sun‐Whe Kim · 4 shared papers, 2015–2021 · strength 0.28
  25. Hye In Lee · 1 shared paper, 2022 · strength 0.26

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.